Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride replaces potassium ions, essential for maintaining cellular membrane potential, acid-base balance, and nerve conduction. Dextrose provides a source of calories and may increase serum osmolality. Sodium chloride restores sodium and chloride ions, correcting extracellular fluid deficits.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Supplementation of potassium in patients with hypokalemia,Maintenance of electrolyte balance in parenteral nutrition
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous infusion; typical adult dose is 1 to 2 L per day, providing 20-40 m Eq potassium chloride (as 0.15% KCl), 50-100 g dextrose, and 154-308 m Eq sodium chloride, adjusted based on serum electrolytes and fluid status.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Not applicable as a terminal elimination half-life; potassium is a physiological ion. Endogenous regulation maintains serum levels. In context, excess potassium is cleared with a functional half-life of about 6-8 hours in patients with normal renal function.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Potassium is primarily excreted unchanged by the kidneys; dextrose is metabolized via glycolysis; sodium and chloride undergo renal reabsorption and excretion.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal excretion of potassium is >90%, with negligible biliary or fecal elimination. Excretion is primarily via kidneys, with potassium filtered, reabsorbed, and secreted by renal tubules.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
0% bound to plasma proteins; potassium exists as free ion.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
0.2-0.5 L/kg; primarily extracellular distribution, with 98% of total body potassium intracellular. Vd reflects rapid equilibration with interstitial fluid.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Intravenous: 100% (complete). Not available orally via this formulation.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
Use with caution; for GFR 30-50 m L/min, reduce potassium chloride to 0.1% or less; for GFR <30 m L/min, avoid potassium chloride due to risk of hyperkalemia. Monitor serum potassium closely.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No specific dose adjustment for hepatic impairment; however, in severe hepatic disease (Child-Pugh C), monitor for fluid overload and electrolyte disturbances.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Weight-based: Potassium chloride 0.5-1 m Eq/kg/day, dextrose 5-10 mg/kg/min, sodium chloride 2-4 m Eq/kg/day, administered as continuous IV infusion at a rate not exceeding 0.5 m Eq/kg/hour for potassium.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Start at lower end of dosing range; monitor renal function and serum electrolytes frequently due to age-related decline in GFR and increased sensitivity to fluid and electrolyte shifts.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
Concentrated potassium chloride solutions are fatal if given undiluted. Must be diluted and administered slowly via IV infusion.
None.
Monitor serum potassium, glucose, and electrolytes frequently. Use with caution in renal impairment, cardiac disease, hyperkalemia, metabolic alkalosis, and conditions predisposing to hyperkalemia. Do not administer if solution contains particulate matter or if container is damaged.
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hyperkalemia, severe renal impairment with oliguria or anuria, untreated Addison's disease, adynamia episodica hereditaria, acute dehydration, heat cramps, patients receiving potassium-sparing diuretics.
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No specific food interactions. Dietary potassium intake should be monitored in patients with hyperkalemia risk.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
No evidence of teratogenicity in animal studies or human case reports. Potassium chloride, dextrose, and sodium chloride are physiologic components at standard concentrations. Not associated with major malformations. Avoid hyperkalemia which may cause fetal arrhythmias.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
All components are endogenous and present in breast milk. No known adverse effects at therapeutic doses. M/P ratio not applicable as these are electrolytes and sugar. Compatible with breastfeeding.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
No specific dose adjustment required. However, pregnancy increases glomerular filtration rate; monitor electrolytes and glucose, adjust rate accordingly to avoid hypo/hyperkalemia or hyperglycemia.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
This combination solution provides maintenance hydration with potassium supplementation. Monitor serum potassium closely in renal impairment, patients on ACE inhibitors/ARBs, or K-sparing diuretics. Contraindicated in hyperkalemia. Infusion rate should not exceed 10 m Eq/hour potassium. Use with caution in heart failure due to sodium content.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This intravenous fluid contains potassium, sodium, and dextrose.,Tell your doctor if you have kidney problems, heart disease, or are taking certain blood pressure medications.,Symptoms of too much potassium include muscle weakness, irregular heartbeat, or confusion.,You may experience discomfort at the IV insertion site.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Potassium chloride replaces potassium ions, essential for maintaining cellular membrane potential, acid-base balance, and nerve conduction. Dextrose provides a source of calories and may increase serum osmolality. Sodium chloride restores sodium and chloride ions, correcting extracellular fluid deficits.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 1 to 2 L per day, providing 20-40 m Eq potassium chloride (as 0.15% KCl), 50-100 g dextrose, and 154-308 m Eq sodium chloride, adjusted based on serum electrolytes and fluid status.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. No evidence of teratogenicity in animal studies or human case reports. Potassium chloride, dextrose, and sodium chloride are physiologic components at standard concentrations. Not . ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.